Premium
Intravenous immunoglobulin in the treatment of neurologic disorders
Author(s) -
Živković S.
Publication year - 2016
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12444
Subject(s) - medicine , chronic inflammatory demyelinating polyneuropathy , multifocal motor neuropathy , myasthenia gravis , intravenous immunoglobulins , autoimmune encephalitis , adverse effect , aseptic meningitis , neurology , dermatomyositis , guillain barre syndrome , intensive care medicine , pediatrics , immunology , antibody , meningitis , autoantibody , dermatology , mismatch negativity , electroencephalography , psychiatry
Intravenous immunoglobulins ( IVIG s) are often used in the treatment of autoimmune disorders and immunodeficiencies, and it has been estimated that neurologic indications can account for up to 43% of IVIG used in clinical practice. In neurologic clinical practice, IVIG is used for acute therapy of newly diagnosed autoimmune disorders or exacerbations of pre‐existing conditions, or as long‐term maintenance treatment for chronic disorders. IVIG exerts its effects on humoral and cell‐based immunity through multiple pathways, without a single dominant mechanism. Clinical use of IVIG has been supported by guidelines from American Academy of Neurology and European Federation of Neurologic Societies. IVIG is generally recommended for the treatment of Guillain–Barre syndrome and chronic inflammatory demyelinating polyneuropathy in adults, multifocal motor neuropathy and myasthenia gravis, and should be considered as a treatment option for dermatomyositis in adults and Lambert–Eaton myasthenic syndrome. Additional potential indications include stiff person syndrome, multiple sclerosis during pregnancy or while breastfeeding, refractory autoimmune epilepsy, and paraneoplastic disorders. Clinical use of IVIG is mostly safe but few adverse effects may still occur with potentially severe complications, including aseptic meningitis and thromboembolism. In addition to intravenous route ( IVIG ), subcutaneous immunoglobulins have been used as an alternative treatment option, especially in patients with limited intravenous access. Treatment with IVIG is effective in various autoimmune diseases, but its broader use is constrained by limited supply. This review evaluates the use of immunoglobulins in treatment of neurologic diseases.